This year’s ASCO conference has plenty of data from the CAR-T therapy contenders - but little known Chinese biotech Nanjing Biotech looks to have trumped all the established firms.
While ASCO often showcases the benefits of new cancer therapies, it was a well-established drug that proved to be a talking point at this year’s conference in Chicago.
